Skip to search boxSkip to navigationSkip to main content

The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures

  • Michael S. Kraus(corresponding author)
    ,
  • James M. Gold
    ,
  • Deanna M. Barch
    ,
  • Trina M. Walker
    ,
  • Charlotte A. Chun
    ,
  • Robert W. Buchanan
*Corresponding author for this work
  • Duke University
    ,
  • University of Maryland, Baltimore
    ,
  • Washington University St. Louis
    ,
  • Temple University
    ,
  • Northwestern University
    ,
  • Massachusetts General Hospital
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological processes that may be aberrant in schizophrenia. However, more information regarding psychometric properties and correlations with standard neuropsychological tests and functional measures is warranted to establish their validity as treatment outcome measures. The N-back and AX-Continuous Performance Task (AX-CPT) are two promising cognitive neuroscience tests designed to measure specific components of working memory and contextual processing respectively. In the current study, we report the psychometric properties of multiple outcome measures from these two tests as well as their correlations with standard neuropsychological measures and functional capacity measures. The results suggest that while the AX-CPT and N-back display favorable psychometric properties, they do not exhibit greater sensitivity or specificity with functional measures than standard neurocognitive tests.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Article number

100161

Journal (Volume, Issue Number)

Schizophrenia Research: Cognition (Volume 19)

Publication milestones

  • Published - 03/2020

Publication status

Published - 03/2020

ISSN

2215-0013

Publication IDs

  • Scopus: 85074487290

Publication metrics

Metrics

Fractional count
1
Fractional count
0.05
Fractional count
21
Fractional count
0.95
Fractional count
1
Fractional count
1
Scopus
citations
SciVal
Author count
22
SciVal
Paper percentile
50

PlumX, opens in new tab

Captures
56
Citation count
5

Funding Details

This study was funded by National Institute of Mental Health Contract HHSN278200441003C to the University of California, Los Angeles (SRM, Principal Investigator). Double-blind medications were provided by Merck and Company.
FundersFunding number
Merck and Company
-
NIMH
HHSN278200441003C